Eledon Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-17.3%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.87next fiscal year
Monitoring Framework
Key Performance Indicators
Tegoprubart Clinical Trial Progress (Phase 2 BESTOW Trial Results) QuarterlyTarget: Presentation of long-term Phase 2 BESTOW trial results at the American Transplant Congress (ATC) 2026
Cash Runway (Months of Funding) Quarterly12.0Target: Fund operations into 2Q 2027
Islet Cell Transplantation Insulin Independence Rate Annually10,000.0%Target: Maintain 100% insulin independence in treated Type 1 Diabetes patients
Watch Items
- Phase 3 Kidney Transplantation Trial InitiationTrigger: Regulatory engagement and agreement on Phase 3 protocol with the FDAAction: Finalize Phase 3 study design and initiate patient enrollment by late 2026
- Transition of Islet Cell Transplant Program to Sponsored StudyTrigger: Filing of an Investigational New Drug (IND) application by year-end 2026Action: Transition investigator-initiated research into a company-sponsored clinical trial
Research as of 19 Jun 2026